1. Home
  2. FMS vs MDGL Comparison

FMS vs MDGL Comparison

Compare FMS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fresenius Medical Care AG

FMS

Fresenius Medical Care AG

HOLD

Current Price

$23.15

Market Cap

12.5B

Sector

Health Care

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$512.65

Market Cap

11.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMS
MDGL
Founded
1996
2011
Country
Germany
United States
Employees
108165
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5B
11.1B
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
FMS
MDGL
Price
$23.15
$512.65
Analyst Decision
Sell
Strong Buy
Analyst Count
2
12
Target Price
$30.00
$674.45
AVG Volume (30 Days)
630.1K
285.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
41.32
EPS
N/A
N/A
Revenue
N/A
$180,133,000.00
Revenue This Year
N/A
$58.39
Revenue Next Year
$3.83
$48.55
P/E Ratio
$15.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.02
$284.02
52 Week High
$28.87
$615.00

Technical Indicators

Market Signals
Indicator
FMS
MDGL
Relative Strength Index (RSI) 55.79 58.07
Support Level $22.50 $498.59
Resistance Level $23.36 $540.72
Average True Range (ATR) 0.29 17.18
MACD 0.04 3.84
Stochastic Oscillator 55.43 79.60

Price Performance

Historical Comparison
FMS
MDGL

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: